Journal List > Chonnam Med J > v.45(1) > 1017933

Kang, Kim, Song, Cho, Park, and Yoon: Efficacy of Amniotic Membrane Transplantation on Corneal Graft Rejection with Epithelial Defects after Penetrating Keratoplasty

Abstract

We report the therapeutic effect of amniotic membrane transplantation (AMT) on corneal graft rejection with epithelial defects after penetrating keratoplasty (PKP). Twelve patients (12 eyes) who had epithelial and subepithelial graft rejection received human AMT, and they were compared with other 12 patients (12 eyes) who were treated with medication only. There were no differences in age, sex, time to rejection after PKP, and epithelial defect area between two groups. Time to epithelial healing and time to disappearance of rejection sign were significantly shorter in the AMT group (11.8±4.9 days and 15.5±6.3 days) than in the medical treatment group (19.0±3.7 days and 20.8±3.4 days)(p=0.01, p=0.02). AMT is effective in promoting epithelialization and improving inflammation of epithelial rejection after penetrating keratoplasty.

Figures and Tables

Fig. 1
Comparison of time to epithelial healing and time to disappearance of rejection sign between the amniotic membrane transplanted group and the medical treatment group.
cmj-45-55-g001
Fig. 2
Preoperative slit-lamp photograph demonstrated epithelial graft rejection showing large epithelial defect and subepithelial infiltration (A). Amniotic membrane was transplanted over the ocular surface (B). Eleven days after operation, the lesion healed with clear cornea (C).
cmj-45-55-g002
Table 1
Characteristics of patients who were treated with amniotic membrane transplantation (AMT) and immunosuppressive agents for corneal graft rejection
cmj-45-55-i001

AM, amniotic membrane; HSK, herpes simplex keratitis; PKP, penetrating keratoplasty.

Table 2
Characteristics of patients who were treated with immunosuppressive agents only for corneal graft rejection
cmj-45-55-i002

HSK, herpes simplex keratitis; PKP, penetrating keratoplasty.

References

1. Foster CS, Azar DT, Dohlman CH. The cornea. 2005. 4th ed. Philadelphia: Lippincott Williams & Wilkins;1035–1061.
2. Fraunfelder FW. Corneal toxicity from topical ocular and systemic medications. Cornea. 2006. 25:1133–1138.
crossref
3. Kim JC, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. Cornea. 1995. 14:473–484.
crossref
4. Hori J, Wang M, Kamiya K, Takahashi H, Sakuragawa N. Immunological characteristics of amniotic epithelium. Cornea. 2006. 25(10):Suppl 1. S53–S58.
crossref
5. Mayer DJ, Casey TA. Reducing the risk of corneal graft rejection. Acomparison of different methods. Cornea. 1987. 6:261–268.
6. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. There manifestations, frequency, preoperative correlates and treatment. Arch Ophthalmol. 1981. 99:599–604.
7. Figueiredo FC, Nicholls SM, Easty DL. Corneal epithelial rejection in the rat. Invest Ophthalmol Vis Sci. 2002. 43:729–736.
8. Prabhasawat P, Tesavibul N, Komolsuradej W. Single and multilayer amniotic membrane transplantation for persistent corneal epithelial defect with and without stromal thinning and perforation. Br J Ophthalmol. 2001. 85:1455–1463.
crossref
9. Spigelman AV, Deutsch TA, Sugar J. Application of homologous fibronectin to persistent human corneal epithelial defect. Cornea. 1987. 6:128–130.
crossref
10. Lee SH, Tseng SC. Amniotic membrane transplantation for persistent epithelial defects with ulceration. Am J Ophthalmol. 1997. 123:303–312.
crossref
11. Dios E, Herreras JM, Mayo A, Blanco G. Efficacy of systemic cyclosporine A and amniotic membrane on rabbit conjunctival limbal allograft rejection. Cornea. 2005. 24:182–188.
crossref
12. Yao YF, Zhang YM, Zou P, Zhang B, Qiu WY, Tseng SC. Therapeutic penetrating keratoplasty in severe fungal keratitis using cryopreserved donor corneas. Br J Ophthalmol. 2003. 87:543–547.
crossref
13. Li DQ, Lee SB, Tseng SC. Differential expression and regulation of TGF-beta1, TGF-beta2, TGF-beta3, TGF-betaRI, TGF-betaRII and TGF-betaRIII in culture human corneal, limbal, and conjunctival fibroblasts. Curr Eye Res. 1999. 19:154–161.
crossref
14. Azuara-Blanco A, Pillai CT, Dua HS. Amniotic membrane transplantation for ocular surface reconstruction. Br J Ophathalmol. 1999. 83:399–402.
crossref
15. Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol. 1989. 107:506–510.
crossref
16. Lim BK, Tchah HW. Effect of topical FK506 at experimental corneal xenograft. J Korean Ophthalmol Soc. 1998. 39:847–854.
17. Xu KP, Wu Y, Zhou J, Zhang X. Survival of rabbit limbal stem cell allografts after administration of cyclosporin A. Cornea. 1999. 18:459–465.
crossref
18. Dua HS, Azuara-Blanco A. Allo-limbal transplantation in patients with limbal stem cell deficiency. Br J Ophthalmol. 1999. 83:414–419.
crossref
19. Holland EF, Djalilian AR, Schwartz GS. Management of aniridic keratopathy with keratolimbal allograft: a limbal stem cell transplantation technique. Ophthalmology. 2003. 110:125–130.
crossref
20. Kim EC, Kim MS. Graft rejection in penetrating keratoplasty. J Korean Ophthalmol Soc. 2003. 44:289–295.
21. Feldman ST. The effect of epidermal growth factor on corneal wound healing: practical considerations for therapeutic use. Refract Corneal Surg. 1991. 7:232–239.
crossref
22. Chen HC, Tan HY, Hsiao CH, Hyang SC, Lin KK, Ma DH. Amniotic membrane transplantation for persistent corneal ulcers and perforations in acute fungal keratitis. Cornea. 2006. 25:564–572.
crossref
TOOLS
Similar articles